Ubs Group Ag Synthetic Biologics, Inc. Call Options Transaction History
Ubs Group Ag
- $452 Billion
- Q3 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
About Synthetic Biologics, Inc.
- Ticker SYN
- Exchange NYSE
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 15,844,100
- Market Cap $9.51M
- Description
- Synthetic Biologics, Inc., a clinical-stage company, develops therapeutics to treat diseases in areas of high unmet need. The company's lead product candidates include SYN-004 designed to degrade various commonly used intravenous beta-lactam antibiotics in gastrointestinal (GI) tract for the prevention of microbiome damage, clostridium difficile...